AstraZeneca has reduced the effectiveness of the US Covid-19 vaccine trial
AstraZeneca has revised the effectiveness of the Covid-19 vaccine trial in the US to 76% as it tried to address concerns that the pharmaceutical group had released incomplete provisional data earlier this week.
Mene Pangalos, AstraZeneca’s executive vice president, said it was reassessed that the data is “consistent” with the previously reported figures, as they have an efficiency rate. 79 percent.
AstraZeneca’s latest challenge escalated for the company a few weeks as the U.S. independent data control committee oversaw its clinical trial in opposition to the initial data release. potentially misleading. The Anglo-Swedish pharmaceutical group has been in a tough fight over allegations against the EU failed to meet supply targets.
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said this week that the data and safety control committee that oversaw the clinical trial had sent a “rather harsh note” to him and AstraZeneca.
The monitoring committee was concerned that the provisional data, by the end of mid-February, would show a more positive efficiency rate, and said the actual rate could be between 69 and 74 per cent.
In response, AstraZeneca expedited its analysis to determine whether each additional case was actually Covid-19.
This “confirms that our Covid-19 vaccine is very effective in adults, those 65 and older,” Pangalos said. The jab, developed with Oxford University, was also found to be effective at 85 per cent in adults, having previously averaged more than 80 per cent and prevented all serious illnesses and hospitalization.
“We hope to present our regulatory shipment for emergency use in the U.S. and prepare to spread millions of doses across America,” Pangalos said.
The U.S. trial drew more than 32,000 participants, two-thirds of whom were vaccinated with one-third in placebo. According to the new analysis, it affected 190 cases of symptomatic Covid-19, 49 more than counted in the initial analysis. There were 14 more cases left to confirm with the name Covid-19, which means that the efficacy rate may vary slightly.
More complete data showed a still higher rate of efficacy than in trials outside the US, which was used in the UK and EU for regulatory approval. This test resulted in an average efficiency rate 70 percent In the prevention of symptomatic Covid-19.
The data will be sent for publication in the coming weeks.
AstraZeneca is also embroiled in a dispute with the EU over alleged supply shortages. The company’s low-cost jab was intended to be a key part of the block’s vaccination efforts.
Italy said on Wednesday he found a warehouse 29m dose of AstraZeneca vaccine at a country facility. The company said it was “wrong” to describe vaccines in this way, adding that the doses are awaiting “quality control” processes.
The revelation sparked further allegations from Brussels, and EU trade commissioner Valdis Dombrovskis said the drug manufacturer had promised to “deliver 30m doses, but they are not even close to that number”.
AstraZeneca said it has made “the best efforts” as required by the contract signed with the European Commission last year, and blamed low yields on products in a Belgian plan due to delays.
The company also said this week that the U.S. Monitoring Committee has examined concerns about the rare blood clots he is associated with the vaccine with the help of an independent neurologist and has found no problems.
Latest coronavirus news
Follow FT’s direct coverage and analysis of the global pandemic and the rapidly evolving economic crisis here.